...
首页> 外文期刊>Journal of Analytical Toxicology >Fatal intoxications associated with the designer opioid AH-7921.
【24h】

Fatal intoxications associated with the designer opioid AH-7921.

机译:与设计者ApioID AH-7921相关的致命毒害。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) is a designer opioid with ~80% of morphine's μ-agonist activity. Over a 6-month period, we encountered nine deaths where AH-7921 was involved and detected in blood from the deceased. Shortly after the last death, on August 1 2013, AH-7921 was scheduled as a narcotic and largely disappeared from the illicit market in Sweden. AH-7921 was measured by a selective liquid chromatography-MS-MS method and the concentrations of AH-7921 ranged from 0.03 to 0.99 μg/g blood. Six of our cases had other drugs of abuse on board and most had other medications such as benzodiazepines, antidepressants and analgesics. However, the other medicinal drugs encountered were present in postmortem therapeutic concentrations and unlikely to have contributed to death. In addition to the parent compound, we identified six possible metabolites where two N-demethylated dominated and four mono-hydroxylated were found in trace amounts in the blood. In conclusion, deaths with AH-7921 seem to occur both at low and high concentrations, probably a result of different tolerance to the drug. Hence, it is reasonable to assume that no sharp dividing line exists between lethal and non-lethal concentrations. Further, poly-drug use did not seem to be a major contributing factor for the fatal outcome.
机译:AH-7921(3,4-二氯-N - [(1-二甲基氨基)环己基甲基]苯甲酰胺)是具有〜80%的吗啡的μ-激动剂活性的设计者阿片类药物。在6个月内,我们遇到了9个死亡,其中AH-7921参与其中,并在死者中检测到血液中。在最后一次死后不久,2013年8月1日,AH-7921被安排为麻醉,并主要从瑞典的非法市场消失。通过选择性液相色谱-SMS-MS方法测量AH-7921,AH-7921的浓度范围为0.03至0.99μg/ g血液。我们的六个案件有其他滥用药物,并且大多数药物有其他药物,如苯二氮卓,抗抑郁药和镇痛药。然而,遇到的其他药物存在于后期治疗浓度中,而不太可能导致死亡。除了母体化合物之外,我们确定了六种可能的代谢物,其中在血液中痕量的痕量发现两个N-脱甲基化的占状金属和四种单羟基化物。总之,与AH-7921的死亡似乎在低浓度和高浓度下发生,可能对药物不同的耐受性。因此,假设在致死和非致命浓度之间没有尖锐的分隔线是合理的。此外,多药物使用似乎并未成为致命结果的主要贡献因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号